专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2022238133A1 METHOD FOR OPERATING A LABORATORY AUTOMATION SYSTEM, LABORATORY AUTOMATION SYSTEM, AND LABORATORY IN-VITRO DIAGNOSTIC SYSTEM 审中-公开
公开(公告)号：WO2022238133A1
公开(公告)日：2022-11-17
申请号：PCT/EP2022/061347
申请日：2022-04-28
申请人： F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS GMBH , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： FERNANDEZ, Josep
IPC分类号： G16H10/40 , G01N35/04 , G01N35/00 , G01N2035/0091 , G01N35/00871
摘要： Roche Diagnostics GmbH et al. R75170WO Abstract The present disclosure refers to a method for operating a laboratory automation sys- tem (407), comprising a plurality of devices (401), a transport system (404), a plurality of transfer devices (402); a portable device; and a plurality of data communication modules.5 The method comprises: receiving device information for the plurality of devices (401) in the portable device, the device information being indicative a device identification; receiving a first user input in the portable device, the user input being indicative of a selection of a first device (401) from the plurality of devices (401); in response to receiving the first user input, pairing the first device (401) with the transport system (404) for data communication in op-10 eration of the first device (401) for at least one of sample pre-analytics and sample analysis; and providing first pairing information in the portable device, the first paring information being indicative of the first device (401) and the distribution system being paired successfully. Fur- ther, a laboratory automation system (407) and a laboratory in-vitro diagnostic system are provided. (Fig. 4a)15

12. 发明申请

WO2022229422A2 IGFBP7 MARKER PANELS FOR EARLY DETECTION OF SEPSIS 审中-公开
公开(公告)号：WO2022229422A2
公开(公告)日：2022-11-03
申请号：PCT/EP2022/061553
申请日：2022-04-29
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： GRUENEWALD, Felix , JEGER, Victor Johann Raul , KLAMMER, Martin , SCHUETZ, Philipp , VON HOLTEY, Maria , WEBER, Stephen , WEGMEYER, Heike , WIENHUES-THELEN, Ursula-Henrike
IPC分类号： G01N33/68 , G01N2800/26 , G01N33/6893
摘要： The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being IGFBP7, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: PCT, IL6, a cardiac Troponin, Albumin, CRP, Bilirubin, Ferritin, ESM-1, Aspartate aminotransferase, a BNP-type peptide, Alanine aminotransferase, Creatinine, and suPAR, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being IGFBP7 and a second biomarker selected from the group consisting of: PCT, IL6, a cardiac Troponin, Albumin, CRP, Bilirubin, Ferritin, ESM-1, Aspartate aminotransferase, a BNP-type peptide, Alanine aminotransferase, Creatinine, and suPAR, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.

13. 发明申请

WO2022229415A2 GDF15 MARKER PANELS FOR EARLY DETECTION OF SEPSIS 审中-公开
公开(公告)号：WO2022229415A2
公开(公告)日：2022-11-03
申请号：PCT/EP2022/061543
申请日：2022-04-29
申请人： F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS GMBH , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： GRUENEWALD, Felix , JEGER, Victor Johann Raul , KLAMMER, Martin , SCHUETZ, Philipp , VON HOLTEY, Maria , WEBER, Stephen , WEGMEYER, Heike , WIENHUES-THELEN, Ursula-Henrike
IPC分类号： G01N33/68 , G01N2800/26 , G01N2800/50 , G01N33/6863 , G01N33/6893
摘要： The present invention relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being GDF-15, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: sFLT1, Cystatin C, IGFBP-7, Bilirubin, ESM-1, sTREM-1, Procalcitonin, cardiac Troponin, BNP-type peptide, Alanine aminotransferase, and Aspartate aminotransferase, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being GDF-15 and a second biomarker selected from the group consisting of sFLT1, Cystatin C, IGFBP-7, Bilirubin, ESM-1, sTREM-1, Procalcitonin, cardiac Troponin, BNP-type peptide, Alanine aminotransferase, and Aspartate aminotransferase or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.

14. 发明申请

WO2022194756A2 COMPOSITIONS AND METHODS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) VARIANTS HAVING SPIKE PROTEIN MUTATIONS 审中-公开
公开(公告)号：WO2022194756A2
公开(公告)日：2022-09-22
申请号：PCT/EP2022/056496
申请日：2022-03-14
申请人： F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS GMBH , ROCHE MOLECULAR SYSTEMS, INC.
发明人： FONTECHA, Marcel R. , MANGIPUDI, Kalyani , MANOHAR, Chitra , SANTINI, Christopher, David , SPIER, Eugene , SUN, Jingtao , YEE, Michelle, E.
IPC分类号： C12Q1/6858 , C12Q1/6844 , C12Q1/70 , C12Q1/6869 , C12Q1/6888 , C12Q1/701
摘要： Methods for the rapid detection of the presence of variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that contain mutations in the Spike (S) protein gene in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting SARS-CoV-2 variants containing S gene mutations and kits are provided that are designed for the detection of SARS-CoV-2 variants containing S gene mutations, in particular the 69-70 deletion, the N501Y and the 484K mutations. Also claimed are specific methods for performing allele-specific amplification employing blocking probes with at least one nucleotide which is an LNA nucleotide.

15. 发明申请

WO2022180204A1 METHOD AND SYSTEM OF MANAGING SAMPLE PRIORITIES 审中-公开
公开(公告)号：WO2022180204A1
公开(公告)日：2022-09-01
申请号：PCT/EP2022/054768
申请日：2022-02-25
申请人： F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS GMBH , ROCHE DIAGNOSTICS OPERATIONS, INC. , HITACHI HIGH-TECH CORPORATION
发明人： LAUBERT, Daniel , SACHSE, Rita , ALDORF, Dennis , RAPP, Werner , HERZOG, Ralf , YAGI, Kenichi , CHIDA, Satoru
IPC分类号： G16H10/40
摘要： The present disclosure relates to a computer implemented method of managing sample processing priorities in a diagnostic laboratory comprising at least one sample processing device (100) connected to a host system (200). The method comprises generating a communication message (20) between the host system (200) and the at least one sample processing device (100) related to a sample processing order (10) received in association with a sample, the message (20) comprising one of at least two priority identifiers (R, S) indicative of respective sample processing priorities from lower priority to higher priority according to the received sample processing order (10). The method further comprises identifying (30) the sample by the at least one sample processing device (100) and processing the sample (31, 32) by the at least one sample processing device (100) according to the sample processing priority (S, R) in the message (20). In case of receiving a subsequent request for change (40) of sample processing priority for the sample from a lower priority to a higher priority after transmission of the message (20) and before the sample is processed, the method comprises changing (50) the message (20) and processing the sample as a higher priority sample (31) instead of as a lower priority sample (32), wherein changing the message (20) comprises changing the lower priority identifier (R) to an identifier (CS) indicative of a change of priority but different from an equivalent higher priority identifier (S) in order to maintain the sample and the sample processing order uniquely identifiable and traceable by both the host system (200) and the at least one sample processing device (100). A respective system for managing sample processing priorities is herein also disclosed.

16. 发明申请

WO2022155607A1 ONCOLOGY WORKFLOW FOR CLINICAL DECISION SUPPORT 审中-公开
公开(公告)号：WO2022155607A1
公开(公告)日：2022-07-21
申请号：PCT/US2022/012814
申请日：2022-01-18
申请人： F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS GMBH , ROCHE MOLECULAR SYSTEMS, INC.
发明人： BARNARD, Cindy K. , BYRAPUNENI, Sambasivarao , CHAPAGAIN, Diwakar , DORGE, Archana P. , JEU, Catherine M. , KESAVAN, Rengaraja , PAREKH, Kaushal D. , RAMANATHAN, Raman , SCHLOSSMAN, David M. , SHARMA, Vishakha
IPC分类号： G16H10/60
摘要： Systems and methods are provided for managing patient data. The system integrates medical data from multiple sources to a unified patient database. Structured and unstructured medical data is obtained, enriched (e.g., by designating data field types, standardizing data types or terminology, and the like), and stored to the unified patient database. The data retrieved from the disparate sources is stored to data elements in the unified patient database in a network of connected objects including data about tumor masses, treatments, reports, medical history, and diagnoses. The data in the unified patient database is used to display patient data in user-friendly interface views, including a patient journey view that displays patient data in a chronological fashion organized by data types. The different interface views can be traversed to display patient data originating from disparate sources with ease, to improve the clinical decision making process.

17. 发明申请

WO2022136621A1 SELECTIVE LYSIS OF HUMAN BLOOD CELLS 审中-公开
公开(公告)号：WO2022136621A1
公开(公告)日：2022-06-30
申请号：PCT/EP2021/087443
申请日：2021-12-23
申请人： F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS GMBH , ROCHE MOLECULAR SYSTEMS, INC.
发明人： DUA, Rajiv , DUGENNY, Slav , ZHANG, Xiaoyun
IPC分类号： C12Q1/6806
摘要： The present invention relates to methods for the specific lysis of eukaryotic cells in a sample containing microorganisms such as bacterium and fungus by incubating the sample in a buffer of around pH 9 that contains a non-ionic detergent.

18. 发明申请

WO2022123061A1 INTERFERENCE MONITORING FOR PROVIDING A VERIFIED ANALYTE MEASUREMENT 审中-公开
公开(公告)号：WO2022123061A1
公开(公告)日：2022-06-16
申请号：PCT/EP2021/085314
申请日：2021-12-10
申请人： F. HOFFMANN-LA ROCHE AG [CH]/[CH] (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CL, CM, CN, CO, CR, CU, CY, CZ, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KM, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MG, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, WS, ZA, ZM, ZW) , ROCHE DIAGNOSTICS OPERATIONS, INC. [US]/[US] (US) , ROCHE DIAGNOSTICS GMBH [DE]/[DE] (DE)
发明人： INTELMANN, Daniel , HEISS, Peter
IPC分类号： G01N30/86 , G01N30/04 , G01N30/88 , G01N30/72
摘要： The present invention relates to a method for providing a verified analyte measurement of a sample with a chromatography mass spectrometer device, said method comprising the following steps: a) admixing an interferent monitoring compound and, optionally an internal standard, to the sample; b) determining a chromatogram of the sample by acquiring a plurality of data points for signal intensities over time for said interferent monitoring compound, said analyte, and optionally said internal standard; and c) comparing a property of an interferent monitoring compound peak to a property of an internal standard peak and/or to a property of an analyte peak; and to methods and systems related thereto.

19. 发明申请

WO2022117625A1 WHOLE TRANSCRIPTOME ANALYSIS IN SINGLE CELLS 审中-公开
公开(公告)号：WO2022117625A1
公开(公告)日：2022-06-09
申请号：PCT/EP2021/083729
申请日：2021-12-01
申请人： F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS GMBH , ROCHE SEQUENCING SOLUTIONS, INC.
发明人： OZTURK, Sedide , RANIK, Martin , RUBELT, Florian
IPC分类号： C12Q1/6806 , C12N15/10
摘要： The invention is a method of single cell transcriptome analysis. The method comprises detecting multiple transcripts in each individual cell of the plurality of cells by barcoding the transcripts with a cell-specific compound barcode formed using a DNA polymerase and a terminal transferase, optionally in a single enzyme such as a reverse transcriptase.

20. 发明申请

WO2022063816A1 COMPUTER-IMPLEMENTED METHOD FOR DETECTING AT LEAST ONE INTERFERENCE AND/OR AT LEAST ONE ARTEFACT IN AT LEAST ONE CHROMATOGRAM 审中-公开
公开(公告)号：WO2022063816A1
公开(公告)日：2022-03-31
申请号：PCT/EP2021/076048
申请日：2021-09-22
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： MICHELY, Julian , REICHERT, Andreas
IPC分类号： G01N30/86 , G01N30/72
摘要： A computer-implemented method for detecting at least one interference and/or at least one artefact in at least one chromatogram determined by at least one mass spectrometry device (110) is proposed. The chromatogram comprises a plurality of raw data points. The method comprises the following steps: a) retrieving the at least one chromatogram by at least one processing device (126); b) applying at least one peak fit modelling to the chromatogram by using the processing device (126); c) determining information about residuals of the raw data points by using the processing device (126); d) detecting the at least one interference and/or the at least one artefact by using the processing device (126) by comparing the determined information about the residuals with at least one pre-determined threshold, wherein, if the determined information about the residuals exceed the pre-determined threshold, the at least one interference and/or the at least one artefact is detected.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式